Head and neck squamous cell carcinomas (HNSCCs) are the eighth most common cancers
worldwide. While promising new therapies are emerging, cisplatin-based chemotherapy …

Head and neck squamous cell carcinoma (HNSCC) is one of the most common malignant
cancers, and patients with HNSCC possess early metastases and poor prognosis …

Study background objectives Cancer poses a significant health concern as it is incurable.
Every year, research on how to treat and eradicate this chronic condition is done. This …

Therapeutic outcomes achieved in head and neck squamous cell carcinoma (HNSCC)
patients by concurrent cisplatin-based chemoradiotherapy initially reflect both tumor …

Aims Pembrolizumab, as monotherapy in first-line recurrent or metastatic (R/M) head and
neck squamous cell carcinoma (HNSCC) with a combined positive score (CPS)≥ 1 and in …

Opinion statement Recurrent and second primary head and neck cancers represent a
clinical challenge due to frequently unresectable and/or locally advanced disease. Given …

There are several controversies in the management of head and neck cancer (SCCHN).
Although combined modality treatment is standard in locally advanced SCCHN (LA …

Abstract < bold> Purpose: </bold> Recurrent nasopharyngeal carcinoma (NPC)
after previous radiation therapy is a significant problem. This study was to determine the …

OBJECTIVE: The aim of this study was to identify features mainly involved in determining the
partial response (PR) to the Electrochemotherapy (ECT) in patients with recurrent and/or …

Background Paclitaxel, carboplatin, and cetuximab (PCC) has shown promise as induction
chemotherapy and in patients with metastatic/recurrent head and neck cancer (HNC). Given …